PDS Biotechnology (PDSB) Total Non-Current Liabilities (2014 - 2019)
PDS Biotechnology's (PDSB) quarterly Total Non-Current Liabilities came in at $2.8 million in Q4 2019, up 44.04% YoY from $1.9 million in Q4 2018, and up 44.04% on a QoQ basis from $1.9 million in Q4 2018.
PDS Biotechnology (PDSB) Total Non-Current Liabilities (2014 - 2019) Analysis & Trends
PDS Biotechnology (PDSB) has 4 years of Total Non-Current Liabilities data on file, last reported at $2.8 million in Q4 2019.
- Quarterly Total Non-Current Liabilities rose 44.04% year-over-year to $2.8 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $2.8 million (up 44.04% YoY) and the FY2019 annual result came in at $2.8 million, up 44.04% from the prior year.
- Total Non-Current Liabilities advanced to $2.8 million in Q4 2019, from $1.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $134.1 million in Q4 2015 to a low of $1.9 million in Q4 2018.
- A 3-year average of $48.4 million and a median of $28.8 million in 2015 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2015 — Total Non-Current Liabilities surged 783.62% — and 2019, when it surged 44.04%.
- Tracing PDSB's Total Non-Current Liabilities over 3 years: stood at $134.1 million in 2015, then slumped by 98.55% to $1.9 million in 2018, then jumped by 44.04% to $2.8 million in 2019.
- The last three Total Non-Current Liabilities figures came in at $2.8 million (Q4 2019), $1.9 million (Q4 2018), and $134.1 million (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 9.32 Bn |
| 10 | PDS Biotechnology | 11.97 Mn | 11.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 2.79 Mn |
| Dec 31, 2018 | 1.94 Mn |
| Dec 31, 2015 | 134.09 Mn |
| Sep 30, 2015 | 54.76 Mn |
| Dec 31, 2014 | 15.18 Mn |